Is DexCom Inc. (NASDAQ:DXCM) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating DexCom Inc. at current levels.
The insulin-user story is mature. The non-insulin type 2 and prediabetes wave is what the market keeps mispricing.
Where DXCM is headed
DexCom in 2028 looks less like a diabetes device company and more like a metabolic health platform with a sensor attached. The insulin-using diabetic base, roughly 8 million addressable patients in the US, has been the entire story for a decade. The next leg is the 25+ million type 2 non-insulin adults and the prediabetes population who now have a reason to wear a sensor thanks to Stelo, GLP-1 co-prescribing patterns, and the CONNECT trial data landing this quarter. That readout matters because it gives payers something concrete to reimburse against for a population insurers have historically waved off as 'lifestyle'.
Read the full Compass Direction on DXCM
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $84.41).
See the full DXCM analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is DexCom Inc. (NASDAQ:DXCM) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating DexCom Inc. at current levels. The insulin-user story is mature. The non-insulin type 2 and prediabetes wave is what the market keeps mispricing.
What is DXCM's Compass Score?
DexCom Inc. scores 90/100 on Alexandria's Compass, placing it in the "True North" tier. Scores blend eight factors and update weekly.
What is the price target for DXCM?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the DXCM page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.